Last reviewed · How we verify
intra-rectal botulinum toxin injections
Botulinum toxin injections work by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation.
Botulinum toxin injections work by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation. Used for Fecal incontinence, Chronic anal fissure.
At a glance
| Generic name | intra-rectal botulinum toxin injections |
|---|---|
| Sponsor | University Hospital, Rouen |
| Drug class | Neuromuscular blocker |
| Target | SNARE proteins |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the cleavage of SNARE proteins by botulinum toxin, preventing the fusion of vesicles containing acetylcholine with the presynaptic membrane. As a result, acetylcholine is not released into the synaptic cleft, and muscle contraction is inhibited. This mechanism is particularly useful for treating conditions characterized by excessive muscle contraction or spasm.
Approved indications
- Fecal incontinence
- Chronic anal fissure
Common side effects
- Anal pain
- Fecal urgency
- Rectal bleeding
Key clinical trials
- Mechanisms of Action on Rectal Motricity of Intrarectal Botulinum Toxin Injections (PHASE3)
- Intra-rectal Botulinum Toxin Injection for Intractable Non-retentive Fecal Incontinence in Children - an Open Label Pilot Study (EARLY_PHASE1)
- The Value of Botox-A for Management of Low Anterior Resection Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: